Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | MAX | P61244 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 7/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807536 | 1.00 | MYC (0.39) | MYCMAXSCDBDKRB1HDAC1 | |
| SCHEMBL2809623 | 0.92 | BDKRB1 (0.39) | MYCMAXSCDBDKRB1HDAC1 | |
| SCHEMBL2809400 | 0.91 | HDAC1 (0.41) | MYCMAXSCDBDKRB1HDAC1 | |
| SCHEMBL2808825 | 0.91 | MYC (0.39) | MYCMAXSCDBDKRB1AURKA | |
| SCHEMBL2809397 | 0.91 | HDAC1 (0.41) | MYCMAXSCDBDKRB1HDAC1 | |
| SCHEMBL2808827 | 0.91 | MYC (0.39) | MYCMAXSCDBDKRB1AURKA | |
| SCHEMBL2808644 | 0.91 | HDAC1 (0.42) | MYCMAXSCDBDKRB1HDAC1 | |
| SCHEMBL2808646 | 0.91 | HDAC1 (0.42) | MYCMAXSCDBDKRB1HDAC1 | |
| SCHEMBL2804848 | 0.90 | BDKRB1 (0.38) | MYCMAXSCDBDKRB1HDAC1 | |
| SCHEMBL2812065 | 0.89 | HDAC3 (0.38) | SCDBDKRB1HDAC1AURKAPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | MYC 4605/4885MAX 3525/4885SCD 4859/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | MYC 4605/4885MAX 3525/4885SCD 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.